Associate Professor, Internal Medicine, Washington University School of Medicine
Oncology
Dr. Steven M. Sorscher, MD
|
|
Give Review
Steven M. Sorscher, MD is an expert in the field of Oncology. He went to medical school at University of Michigan Medical School. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Steven M. Sorscher, MD has written publications. He has 43 publications published with PubMed. The lastest publication is: 'BCRA 1 testing guidelines for high-risk patients.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in a resected pancreaticoBiliary carcinoma.
- Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic Neuroendocrine tumor.
- Clinical confirmation of an anti-metastasis effect from statins.
- Five Fractions of Radiation Therapy Followed by 4 Cycles of FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer.
- Metastatic pancreatic poorly differentiated Neuroendocrine carcinoma: current treatment considerations.
- Emil Frei's Contributions.
- A molecularly confirmed Neuroendocrine tumor resulting from Lynch Syndrome.
- Acinar Cell Carcinoma Responding to Carboplatin/Etoposide Chemotherapy.
- Ras Inhibition and the Survival Benefit Favoring Zoledronic Acid Compared With Denosumab in Patients With Multiple Myeloma.
- Spontaneous inactivating p53 mutations and the "selfish Cell".
- Antiemesis. Clinical Practice Guidelines in Oncology.
- Metastasis in von hippel-lindau disease.
- HER-2 overexpression in Breast tumors lacking gene amplification.
- EGFR mutations and sensitivity to gefitinib.
- Withdrawal of immunosuppressive therapy after developing Melanoma.
- Predicting recurrence risk for synchronous primary colon Cancers.
- Electrolyte abnormalities with zoledronic acid therapy.
- Probable serotonin syndrome variant in a patient receiving a selective serotonin reuptake inhibitor and a 5-HT3 receptor antagonist.
- Marked radiographic response of a HER-2-overexpressing biliary Cancer to trastuzumab.
- Are targeted therapies a consideration in poorly differentiated Neuroendocrine tumors?
- BCRA 1 testing guidelines for high-risk patients.
- Microinjection of an nm23 specific antibody inhibits Cell division in rat embryo fibroblasts.
- Enhanced E-cadherin expression in epidermal growth factor receptor expressing Cells.
- Immunolocalization of E-cadherin in human head and neck Cancer.
- Immunohistochemical evaluation of E-cadherin and epidermal growth factor receptor in non-small cell lung Cancer.
- Antidepressant-induced sexual dysfunction in men: due to cholinergic blockade?
- Conjugated Bile acid uptake by Xenopus laevis oocytes induced by microinjection with ileal Poly A+ mRNA.
- Hepatocellular carcinoma developing years after extended field radiation for Hodgkin''s Lymphoma.
- Evolutionary maintenance of oncogenesis.
- Is oncogenesis a normal Cellular defense mechanism?
- Biological therapy update in colorectal Cancer.
- 54-year-old man with breast Cancer after prolonged testosterone therapy.
- 31-year-old female with a prior breast Cancer and strong breast Cancer family history who continues to menstruate after chemotherapy.
- Urethral ''recurrence'' found 14 years after radical cystectomy.
- Penile involvement with hand-foot syndrome.
- Estimating recurrence probability for synchronous breast Cancers.
- Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate Cancer.
- Elevated parathyroid hormone-related peptide in a patient with an extragonadal germ-Cell tumour and hypercalcemia.
- Prognostic markers in resected stage I and II non small-cell lung Cancer: an analysis of 260 patients with 5 year follow-up.
- Metastatic acinar Cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
- FDA-approved drugs.
- Marked response to single agent trastuzumab in a patient with metastatic HER-2 gene amplified rectal Cancer.
Schools
University of Mi Med Sch
University Of Michigan
University Of California San Diego
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of California San Diego -
University of Michigan Hospitals and Health Centers -
University of Michigan Medical School
Drug Facts
| NPI NUMBER | 1962429597 | |
| NPPES Provider LastName | SORSCHER | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 764.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 109.0 | |
| Percent Opioid Claims | 14.27 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1962429597 |
| Last Name Of The Provider | SORSCHER |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
|
Dr. Mary M. Klix, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter D. Weiss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Camille N. Abboud, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Pincus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin R. Tan Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Christos N. Papageorgiou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John F. Dipersio, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|